Our findings further indicated that tumor-specific cellular immunity was downregulated in high-risk individuals compared to low-risk patients and immunohistochemistry analysis found that FOXP3+ Treg was significantly downregulated in LUSC. This evidence concerns the gene FOXP3 and neoplasm.